MIM
ZBIO

Monashee Investment Management’s Zenas BioPharma ZBIO Stock Holding History

Monashee Investment Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.93M Buy
+150,000
New +$3.37M 1.6% 20
2024
Q4 		– Sell
-150,000
Closed -$2.54M – 123
2024
Q3 		$2.54M Buy
+150,000
New +$2.7M 0.27% 53

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Monashee Investment Management's ZBIO Position: Q1 2026 in Review

Monashee Investment Management opened a new position in Zenas BioPharma (ZBIO) in Q1 2026: 150,000 shares worth $2.93M. The stake represents 1.6% of the portfolio and ranks #20 among its holdings. This is a return to the name: Monashee Investment Management previously reported a position in ZBIO as recently as Q3 2024.

Monashee Investment Management first reported a position in ZBIO in Q3 2024 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Monashee Investment Management held 150,000 shares of Zenas BioPharma worth $2.93M as of Q1 2026.
  • Zenas BioPharma was a new Monashee Investment Management position in Q1 2026.
  • Zenas BioPharma made up 1.6% of Monashee Investment Management's portfolio in Q1 2026, its #20 holding.
  • Monashee Investment Management first reported a position in Zenas BioPharma in Q3 2024 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.